
Share
Jonathan Bush's startup bets that connected patient records, not flashy copilots, will be the real moat in healthcare AI. Drive Capital leads a round that pushes total funding past $100 million.
The healthcare AI gold rush has mostly chased applications: copilots, scribes, chatbots. Zus Health is chasing something less glamorous but arguably more durable: the data plumbing those applications depend on.
The company, founded by athenahealth veteran Jonathan Bush, has closed a $33 million Series B led by Drive Capital. Sanofi Ventures, HealthX Ventures and Alumni Ventures joined as new backers, alongside returning investors Andreessen Horowitz, F-Prime, Maverick Ventures and JAZZ Venture Partners. The round brings Zus's total capital raised to more than $100 million since its 2021 launch.
The thesis is straightforward. EHR systems digitized healthcare records but never made them portable across organizations. Clinicians still burn hours hunting down charts and reconciling incomplete histories. Patients still repeat their medical backstory at every new appointment. Bush argues that AI tools built on top of fragmented data inherit that fragmentation, no matter how sophisticated the model underneath.
Zus's answer is what it calls an "always-on, FHIR-native, API-first medical record," built in three layers: a nationwide patient record, a data network that feeds it, and now AI-enabled workflows that act on it. The centerpiece is the Zus Aggregated Profile, a continuously updated longitudinal record that pulls in EHR data, pharmacy records, lab results and care event notifications without requiring customers to build their own connectivity infrastructure.
Zus is leaning on usage metrics to make its case rather than user counts or logos alone. The company says its network supported more than 110 million networked transactions in August alone. Its AI-native clinical platform has generated 39 million evidence citations year-to-date across customer solutions. Those are the kinds of throughput numbers infrastructure plays need to show before anyone takes "platform" claims seriously.
The customer base spans value-based care organizations, digital health companies, provider groups, and diagnostics and precision medicine firms. Specialty care, particularly oncology, is cited as an area of rapid growth. Oncology patient records are notoriously scattered across multiple providers, and reviewing treatment eligibility, clinical trial criteria and genetic testing traditionally eats up significant nurse and analyst time inside fragmented legacy EHR systems. Bush says Zus's continuously aggregated data shortens that manual review cycle meaningfully.
The new capital will go toward three things: expanding AI-powered clinical intelligence capabilities, broadening data network connectivity, and building out workflow automation for population health and care management. Zus also wants to let customers and third-party developers build their own AI-powered workflows on top of its data layer, covering value-based care, specialty care and other high-value use cases.
"We're finally on to the last and critical piece of what I think the future of medical records looks like, which is standing up workflows that automate all of the tasks of patient care in a very bespoke way," Bush told Fierce Healthcare. He framed the bigger stakes bluntly: "Whether Zus wins or somebody else beats Zus at it, all electronic medical records in the future will be national."
Molly Bonakdarpour, general partner at Drive Capital, backed that framing in a statement announcing the round. "We believe healthcare is entering a new era in which AI can fundamentally change how care is delivered, but that transformation depends on having reliable, connected patient information," she said. "Zus has built the foundation to address that challenge at scale."

The strategic bet here is that infrastructure, not applications, becomes the enduring moat in healthcare AI. That's a familiar pattern from other technology cycles: picks-and-shovels providers often outlast the first wave of flashy end-user products built on top of them. If Zus is right, the company that controls the connective tissue between fragmented patient records and AI applications captures value regardless of which specific copilot or agent wins in any given specialty.
It's also a recognition of a structural weakness in the current EHR landscape. Epic and other incumbents dominate record-keeping within individual health systems but were never built for cross-organization portability. That gap is precisely where Zus is positioning itself, and it's notable that the company counts Fierce 15 of 2025 recognition among its credentials, a signal the industry already sees it as one to watch.
Infrastructure plays carry their own risks. Zus depends on continued cooperation from EHR vendors, payers and data networks to keep its connectivity current, and any of those parties could tighten access or compete directly. Epic, for instance, remains the dominant player in EHR software and has its own data exchange ambitions through Care Everywhere.
Monetization is another open question. Zus's metrics, 110 million transactions, 39 million evidence citations, demonstrate activity but not yet profitability or even disclosed revenue figures. A $100 million cumulative raise across multiple rounds since 2021 suggests a capital-intensive build, and infrastructure businesses often require years of investment before unit economics turn favorable. Investors should watch for revenue disclosures or customer retention data in future funding announcements.
Regulatory exposure also looms over the broader sector. Interoperability and patient data access are increasingly contested terrain, as evidenced by Texas's ongoing antitrust suit against Epic over EHR market practices. Any company built around aggregating patient records across organizations will need to navigate a regulatory environment that is still being written.
For investors tracking healthcare AI, Zus Health represents a bet on infrastructure over application layer differentiation, a thesis with precedent in other tech cycles but unproven economics in healthcare specifically. The $33 million round, backed by a mix of strategic and financial investors including Sanofi Ventures, suggests industry confidence in the data-layer thesis. Whether that confidence translates into durable revenue remains the metric to track. With total funding now above $100 million, Zus has runway to prove out its workflow automation ambitions in oncology and value-based care before facing the harder test: converting network scale into sustainable margins.
Tags
Original Sources
Zus Health secures $33M to build the infrastructure for AI-powered clinical workflows
↗ https://www.fiercehealthcare.com/health-tech/zus-health-secures-33m-build-infrastructure-ai-powered-clinical-workflows
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
13 November 2026
14 articles
Related Articles
Related Articles
More Stories
© 2026 Cedar & Bloom. All rights reserved.